ABSTRACT
The development of significant atheromatous plaque narrowing in coronary arteries has a major impact on population morbidity and mortality and thus on health resources. While, ideally, the aim should be the prevention of the plaque formation in the first place, until a cost effective programme of early detection and prevention is available, treatment of the consequences of atheromatous plaque development will continue to play a major role in limiting patient symptoms and altering the natural history of the disease.
